SCHEMBL2362914

SCHEMBL2362914

COc1cc(C(=O)N2CCC(CO)C2)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PDK2 Q15119 1/20 0.38
RBP4 P02753 2/20 0.38
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPK14 Q16539 1/20 0.37
HTR2C P28335 2/20 0.36
GAA P10253 2/20 0.35
CCR8 P51685 1/20 0.35
KCNH2 Q12809 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35
GRM3 Q14832 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2361756 0.85 JAK2 (0.42) GAACCR8KCNH2
SCHEMBL2362966 0.84 HCRTR1 (0.36) PDK2RBP4GAACCR8KCNH2
SCHEMBL2350049 0.83 LPAR5 (0.42) CYP2C9CYP2C19MAPK14CCR8KCNH2
SCHEMBL3309855 0.82 HSP90AA1 (0.40) MAPK14CCR8KCNH2MEN1KMT2A
SCHEMBL3314653 0.82 SPR (0.41) RBP4CYP2C9CYP2C19MAPK14GAA
SCHEMBL2362947 0.82 NPC1 (0.43) NPC1RAB9AGAAKMT2AALDH1A1
SCHEMBL2361926 0.81 CCR8 (0.38) MAPK14CCR8KCNH2MEN1KMT2A
SCHEMBL3348570 0.81 CCR8 (0.43) PDK2MAPK14CCR8KCNH2MEN1
SCHEMBL2362969 0.80 DRD3 (0.42) NPC1RAB9AMAPK14GAACCR8
SCHEMBL1542837 0.79 CYP3A4 (0.43) NPC1RAB9AGAAGRM3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B NPC1 970/4885RAB9A 859/4885PDK2 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.